Navigation Links
Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
Date:5/27/2008

f our TOPS(TM) clinical study represents the culmination of a lot of hard work and support by individuals both inside and outside the organization. We are especially grateful to all of our investigators for their input, dedication and support over the past several months. We are all very excited to get started again."

Impliant has enrolled 74 patients to date in its prospective, randomized IDE study comparing the TOPS(TM) System to a traditional posterior fusion. The company also currently has 75 TOPS(TM) patients enrolled under single and multi-level protocols in Brazil, Belgium, Turkey, and Israel. Page 2 of 2

Impliant is applying cutting-edge materials and crossbar biomechanical techniques to develop a new class of spine arthroplasty devices that target over 40% of the patients worldwide who undergo fusion surgery and could benefit from a Total Posterior Arthroplasty solution.

About the TOPS(TM) System

Impliant's TOPS(TM) System, a mobile posterior device, is designed to stabilize but not fuse the L3-4 or L4-5 vertebral level to alleviate pain stemming from spinal stenosis with or without degenerative facet arthrosis and spondylolisthesis. Following a laminectomy and medial facetectomy, the device is affixed to the spine via four pedicle screws using a standard posterior surgical approach. Impliant believes that the TOPS(TM) System could benefit over 500,000 patients worldwide undergoing spinal fusion surgery each year. The TOPS(TM) System is not approved for sale in the United States.

About Impliant, Inc.

Impliant, Inc. is a privately held company engaged in the development of novel spine arthroplasty solutions for some of the most prevalent pathologies of the spine. The company is currently developing the TOPS(TM) System, which has the longest clinical history in the Total Posterior Arthroplasty market segment, dating to January 2005. Impliant is also developing several next- generation and multi-level technologies to f
'/>"/>

SOURCE Impliant, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 17 Cell Therapeutics, Inc. (CTI) ... on February 10, 2010 the U.S. Food ... (ODAC) will review the New Drug Application ... relapsed/refractory aggressive non-Hodgkin,s lymphoma (NHL). ODAC is ... data concerning the efficacy and safety of ...
(Date:12/16/2009)... Medlytix, a national healthcare consulting firm, ... half-billion dollar milestone - the total amount of ... financial assistance to more than a half-million patients ... classifying charity care - in less than two ... hospitals enhanced their bottom lines and still were ...
(Date:12/16/2009)... Dec. 16 Ethicon, Inc., a Johnson ... and a worldwide leader in surgical care, and ... dedicated to designing, developing and commercializing devices that ... (ENT), today announced a definitive merger agreement whereby ... for approximately $785 million net of estimated cash ...
Breaking Medicine Technology:Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4Healthcare Scoring System Allows Hospitals To Increase Charity Care 2Healthcare Scoring System Allows Hospitals To Increase Charity Care 3Healthcare Scoring System Allows Hospitals To Increase Charity Care 4Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer 3A New Hotline Report to Aid Healthcare Decision Make 6429 1ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer 3A New Hotline Report to Aid Healthcare Decision Make 6429 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer 3A New Hotline Report to Aid Healthcare Decision Make 6429 3Biologists discover bacterial defense mechanism against aggressive oxygen 10837 1Biologists discover bacterial defense mechanism against aggressive oxygen 10837 2Lehigh receives grant to reduce cost of carbon capture at coal fired power plants 10833 1Lehigh receives grant to reduce cost of carbon capture at coal fired power plants 10833 2Lehigh receives grant to reduce cost of carbon capture at coal fired power plants 10833 3
... June 25 Vical Incorporated,(Nasdaq: VICL ) ... milestones under a three-year, $6.0 million grant awarded ... a DNA vaccine manufacturing,process with the potential to ... of days., The RapidResponse(TM) system is designed ...
... Initiates a Phase I/II Study of Zalutumumab in Combination, ... Head and Neck Cancer., COPENHAGEN, June 24 ... Phase I/II study of zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy ... study will include a maximum of 36,patients who are ...
Other Medicine Technology:Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 2Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 3Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 4Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 5Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3
(Date:12/17/2009)... CDC,s Morbidity and Mortality Weekly Report (MMWR) released ... epidemiologists has decreased steadily since 2004, with a ... was also a substantial decrease in core epidemiology ... for bioterrorism and emergency response. For ... substance abuse, and oral health, basic epidemiology capacity ...
(Date:12/17/2009)... Good Samaritan Hospital is changing the way women manage ... of the Good Samaritan Hospital Women,s Center For Bladder ... help treat two common medical problems - lack of ... uterus or rectum (pelvic organ prolapse). Three out of ... one out of three may experience pelvic organ prolapse, ...
(Date:12/17/2009)... OAKLAND, Calif., Dec. 17 Today, SEIU ... that Alameda County In-Home Supportive Service (IHSS) providers ... contract with the County that adds multiple layers ... and benefit levels, as well as granting additional ... joining the Governor,s desire to slash homecare provider ...
(Date:12/17/2009)... WALTHAM, MA Brandeis University selected Jay and Maureen Neitz, ... the use of gene therapy to treat vision disorders, ... Award in Vision Sciences. , The award is funded ... a gift from Brandeis graduates Jay Pepose ,75 and ... supports graduate research fellowships in vision science. , The ...
(Date:12/17/2009)... hospital clients Rutherford Hospital Inc. (Rutherfordton, N.C.), a management ... management client since 1992, were recently recognized as top-ranked ... ... Brentwood, Tenn. (PRWEB) ... Rutherford Hospital Inc. (Rutherfordton, N.C.), a management client since ...
Breaking Medicine News(10 mins):Health News:CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 3Health News:New Alameda County IHSS Contract Sends Clear Message to Elected Leaders That Homecare Program Must Remain a California Priority 2Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:QHR Client Hospitals in North Carolina, Michigan Lauded for Providing Community Value 2
... The Procter & Gamble,Company (NYSE: PG ... New York City,beginning at 8:30 a.m. Eastern Time. ... and the Company,s executive management team will,provide a review ... growth opportunities. , ...
... commissioned insurance sales agents in Canada are on the rise ... ... recent reports by Statistics Canada that unemployment is growing and consumer ... supplemental insurance, reports job opportunities for commissioned insurance sales agents in ...
... ... Panama City, FL (PRWEB) December 11, 2008 -- iSirona®, an ... that Peter Witonsky has been named president and chief sales officer. ... over the past 12 months. Company founder and former President Dave ...
... of Electronic Medical Record and practice billing solutions for the healthcare ... company as Chief Commercial Officer. Flormann brings 25 years of ... business and market development to Glenwood Systems. , ... ...
... OH, December 11, 2008 -- More than half a million ... and preterm births are on the rise. Late preterm ... (approximately 4 to 6 weeks before the mother,s due date), ... the large number of affected babies, many people are unaware ...
... ACEL ) today reported its financial results for the first quarter ... company recorded a net loss of approximately $2.8 million, or $0.06 ... Oct. 31., compared to a net loss of $2.7 million, or ... of fiscal 2008. Research and development expenses increased by approximately ...
Other Medicine News:Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 2Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 3Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 4Health News:Insurance Job Opportunities Rise in Canada in Spite of Challenging Economy 2Health News:Insurance Job Opportunities Rise in Canada in Spite of Challenging Economy 3Health News:iSirona Announces New President and Chief Sales Officer 2Health News:Glenwood Systems, LLC Appoints Ron Flormann Chief Commercial Officer 2Health News:Late preterm births present serious risks to newborns 2Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 2Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 3Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 4Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 5
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: